Pyrimethamine (50 mg) with folinic acid (15 mg) given three times weekly was assessed as primary prophylaxis for toxoplasmic encephalitis (TE) in 554 human immunodeficiency virus-infected patients seropositive for Toxoplasma gondii and with <200 CD4 cells/mm". At 1 year, the incidence of TE was similar in pyrimethamine, 12%, and placebo, 13%, groups (relative risk [RR], 0.9; 95% confidence interval [CI], 0.6-1.4), and the survival rate was also similar, 85% and 80%, respectively (RR, 0.9; 95% CI, 0.7-1.2). Rash was the only adverse event that appeared significantly more frequently in the pyrimethamine arm (7% vs. 1%). In the on-treatment analysis, the incidence of TE was lower in the pyrimethamine arm, 4%, than in the placebo arm, 12% (P < .006). Thus, pyrimethamine cannot be recommended as a first-line regimen for primary prophylaxis of TE if the patient can take cotrimoxazole. However, it should be considered for patients who are intolerant to cotrimoxazole, especially in high-risk patients with <100 CD4 cells/nun".
in patients with latent infection: Grant et a1. [6] estimated the risk of infection with TE for AIDS patients who are seropositive for Toxoplasma gondii to be 26% within 2 years after the onset of AIDS, while TE occurs rarely during this period in AIDS patients who are seronegative for the parasite [6] . Second, several clinical series have shown that TE occurs in patients with low CD4 cell counts [3] . No prospective study, however, has precisely estimated the risk of acquiring TE in relation to CD4 cell count.
When this trial was planned in 1989, the number of drugs available for the primary prophylaxis of toxoplasmosis was limited. Cotrimoxazole was found to have some activity against the parasite [7, 8] ; however, it was less active than pyrimethamine in vitro and in mice, and its use was associated with a high prevalence of adverse effects in HIV-infected patients [9] . For >40 years, pyrimethamine has been the compound most active against T. gondii in vitro and in animal studies [10, 11] . It is recommended in combination with sulfonamides or clindamycin for acute treatment ofTE and prevention ofrelapse in HIV-infected patients [1, 2, 4] . Retrospective studies have indicated that increased doses of pyrimethamine as a single agent may be effective for secondary prophylaxis of toxoplasmosis [12] .
Patients who are candidates for primary prophylaxis usually have a preserved quality of life, so the benefit of a potential regimen must be weighed against the risk of unacceptable adverse events. Therefore, pyrimethamine as monotherapy appeared to be the most promising agent for evaluation as primary treatment for prevention of toxoplasmosis. rm 1996;173 (January) By 1989, no regimen had been proven effective for the prevention of TE, and a trial was designed to assess the efficacy and safety of pyrimethamine as primary prophylaxis against TE in HIV-infected patients.
Patients and Methods
Trial design. The placebo-controlled study was a randomized, double-blind trial that compared patients who received pyrimethamine plus folinic acid with patients who received a placebo plus folinic acid. Patients were recruited in France, the United States, and Spain. Randomization was stratified by each participating center. The number of patients (n = 500) and the duration of the study (3 years) were determined on the basis of a 90% power to detect a 50% reduction of the projected rate of occurrence of TE, estimated to be 20% at 3 years in the placebo group.
Patients. Patients were eligible for the study if, at the preinclusion visit (within 4 weeks before randomization), they had HIV-1 infection confirmed by Western blot and <200 CD4 cells/mm" and were positive by ELISA or immunofluorescence for T. gondii.
Patients were excluded if they were < 18 years old, had current clinical or radiologic manifestations consistent with TE, had had a previous adverse reaction to pyrimethamine, received any other drug known to be active against the parasite (cotrimoxazole, sulfonamides, dapsone, macrolides, 5 fluorouracil) within the previous 6 months, or had a hemoglobin level < 10 g/dL, neutrophil count < 1000/mm 3 , platelet count <75,000/mm 3 , serum creatinine higher than 2.0 mg/dL, serum transaminases more than five times the upper limit of the normal range, a known glucose 6 phosphate dehydrogenase deficiency, or were pregnant or had a Karnofsky index <70.
Treatment and patient evaluation. Pyrimethamine (Specia, Paris, and Wellcome, Research Triangle Park, NC) was administered in 50-mg oral doses three times a week after a 100-mg loading dose on the first day. The placebo was similar in appearance and taste to pyrimethamine; one tablet was given three times a week. Folinic acid (Lederle, Paris, and Lederle-Praxis Biologicals Division, Wayne, NJ) was given (15 mg orally 3 times a week) to both groups to counteract the hematologic toxicity of pyrimethamine [13] . At entry, patients received primary pneumocystosis prophylaxis with aerosolized pentamidine, 300 mg every 4 weeks. Antiretroviral therapy with zidovudine or didanosine (after 1992) was allowed. Participants were evaluated every 2 months for fever, neurologic manifestations, and selected laboratory parameters. CD4 cell counts were evaluated every 4 months. Patients were classified according to their CDC HIV clinical status: stage II or III (asymptomatic HIV infection) or stage IV (symptomatic infection), with 2 subgroups, AIDS and non-AIDS, as defined in 1987 [14] .
Brain computed tomography (CT) or magnetic resonance imaging (MRI) was done at entry, once a year when possible, and in cases of clinical manifestations suggestive of central nervous system disease.
Study medication was stopped temporarily if patients developed hemoglobin levels <8 g/dL, neutrophil counts <750/mm pected, no specific drug management strategy was recommended for skin rash. For patients who developed pneumocystosis during the trial, secondary prophylaxis with cotrimoxazole was recommended in October 1991 [15] .
Levels of pyrimethamine were determined as previously described [16] in serum samples at 4, 12, and 24 months.
End points and documentation ofcritical events. The primary end point was occurrence of definite or probable TE. Secondary end points were death, adverse events (rash, hematotoxicity, gastrointestinal toxicity, and other events), noncerebral toxoplasmosis, or pneumocystosis. During the study, all critical events were validated by an event documentation committee prior to unblinding.
TE was considered definite if T. gondii was visualized or isolated from blood or any tissue and if there were clinical and radiologic manifestations compatible with TE. TE was considered probable if characteristic lesions were present on brain CT scan or MRl and if clinical and radiologic abnormalities improved with specific therapy. TE was considered possible when radiologic lesions were not characteristic of toxoplasmosis or when response to acute therapy was not sufficient or assessable. Recommended standard therapy for suspected TE consisted of pyrimethamine (50-75 mg/day) with sulfadiazine (4-6 g/day) or, alternatively, clindamycin (2.4 g/day).
For each death, clinical data and available brain CT or MRl scans were reviewed to determine any relationship to toxoplasmosis. Deaths were classified as related to a first or relapse episode of TE or to unexplained neurologic disorders or as unrelated to toxoplasmosis.
Adverse events were graded in severity from I to 4, according to the National Institute of Allergy and Infectious Diseases standardized toxicity-grading table.
Statistical analysis and study termination. Primary analysis was based on an intention-to-treat approach. Comparison of end points used time-to-failure methods, including Kaplan-Meier estimation and log rank testing. Multivariate analysis used Cox's proportional hazard models; this allowed for the estimate of relative risks (RR) of TE between the 2 treatment groups, adjusting for other covariates at baseline [17] . These models were also used to build predictive models of TE. Two-sided P values are reported for statistical tests. Two interim analyses were planned when the number of toxoplasmic events reached one-third and then twothirds of the expected total. An independent international board (Data Safety Monitoring Board) reviewed these interim analyses.
By December 1992, a considerable amount of data was available from prospective studies that suggested that cotrimoxazole should be recommended as the first-line regimen for primary prophylaxis of pneumocystosis. Cotrimoxazole was also known to have a preventive effect against toxoplasmosis [18] [19] [20] . Because ofthis new information, the study team recommended that all sulfa-tolerant trial participants should be offered cotrimoxazole prophylaxis and discontinued from the study drug. After considering the impact of this recommendation and reviewing an interim analysis of the data base as of 30 November 1992, the Data Safety Monitoring Board recommended study termination in April 1993. Unblinded data were provided to the investigators by 14 April 1993.
Results
Baseline characteristics. A total of 554 patients (433 from France, 112 from the US, and 9 from Spain) were randomized Table 1 . Baseline characteristics of Hlv-infected patients in a primary prophylaxis trial for toxoplasmic encephalitis, using pyrimethamine and placebo, and follow-up. tween the 2 groups. In the placebo group, 11 (5.3%) of 208 patients had pyrimethamine detectable in serum, whereas 17 (9.3%) of 183 patients in the pyrimethamine group had undetectable levels in serum.
Occurrence of toxoplasmosis: intention-to-treat analysis. Eighty-nine patients developed definite or probable TE: 43 in the pyrimethamine group, 46 in the placebo group. The estimated incidence after 1 year was not different between the pyrimethamine(12%) and placebo (13%) groups (RR, 0.9; 95% confidence interval [Cl], 0.6-1.4; P = .76; table 2). TE was documented as definite in 6 patients and probable in 83, with a similar distribution in both groups. The results were unchanged when the analysis included either the possible TE or noncerebral toxoplasmosis patients and after adjustment for baseline characteristics. The results were also unchanged when the cases ofTE recorded between 30 November 1992 and 14 April 1993 were included: 4 in the pyrimethamine group, 8 in the placebo group.
In the multivariate analysis, factors other than treatment group appeared to be significantly predictive of the development of TE: a lower age (for a 10-year difference: RR, 1.3; 95% CI, 1.1-1.6), AIDS compared with asymptomatic HIV infection (RR, 3.1; 95% CI, 1.7-5.7), stage IV non-AIDS compared with asymptomatic HIV infection (RR, 2.3; 95% CI, 1.2-4.1), and <50 CD4 cells/nun" compared with >50/mm 3 (RR, 2.2; 95% CI, 1.4-3.4). Median CD4 cell counts obtained within the 4 months before a diagnosis of TE did not differ between the pyrimethamine (34 cells/rum'; range, 2-185) and Table 2 . Major events during the course of a primary prophylaxis trial for toxoplasmic encephalitis (TE) using pyrimethamine andplacebo in mv-infected patients.
NOTE. Data are no. ofevents (% l-year incidence). *Pulmonary (I),disseminated (3). t 4 patients ineach treatment group. ! Requiring discontinuation of study drug.
§ Myalgias (2), increased creatinine serum level (1), headaches (2), eosinophilia (1) .
between February 1990 and February 1992 to either the pyrimethamine (274) or placebo (280) group. The 2 groups were comparable in most baseline characteristics(table 1). A similar proportion of patients had >200 CD4 cells/mrn' before study entry: 1.8% and 2.8% in the pyrimethamine and placebo groups, respectively. The daily dose (mean ± SD) of zidovudine at day 0 was similar in the 2 groups: 599 ::t:: 164 mg in the pyrimethaminegroup, 597 ::t:: 177 mg in the placebo group.
Follow-up. As of 30 November 1992, 353 patients were being followed; 25 (4.5%) had been lost to follow-up, and 176 (32%) had died. Total duration of follow-up was 653 patientyears, and mean follow-up was 14.1 months ( Since the baseline CD4 cell count appeared to be significantly associated with the risk of developing TE, patients were distributed into two strata. In patients with > 100 CD4 cells/ mm' (390 patient-years), the rate of occurrence of confirmed and probable TE and other forms of toxoplasmosis was slightly higher in the pyrimethamine (12% at 1 year) than in the placebo (8% at 1 year) group. In patients with < 100/mm 3 (263 patientyears), the rate of toxoplasmosis was lower in the pyrimethamine (11% at 1 year) than the placebo (21% at 1 year) group (test of interaction, P = .10).
On-treatment analysis of the occurrence of toxoplasmosis. Because many patients discontinued the study drug due to an adverse event (75/554, 14%) or other reason (128/554, 23%), an analysis was done including only toxoplasmosis end points in patients still receiving the study drug. Fifty-three (60%) of the 89 cases ofTE occurred in patients still receiving pyrimethamine (15) or placebo (38). The l-year incidence of TE was lower in the pyrimethamine (4%) than placebo (12%) group (RR, 004; 95% CI, 0.2-0.8; P < .006; figure 1 ).
Thirty-six of the TE cases occurred after the patients had discontinued study medication. The l-year incidence of TE in patients who discontinued the study drug differed depending on the reason for discontinuation: adverse event, 25% and 15% in the pyrimethamine and placebo groups, respectively; other reasons, 15% and 5% in the pyrimethamine and placebo groups, respectively. The rate of occurrence of TE was even higher in the subgroup of patients who discontinued pyrimethamine due to rash (37% at 1 year, 50% at 18 months). Of interest, in the 11 patients who developed toxoplasmosis after discontinuing pyrimethamine because of a rash, the drug was reintroduced for acute therapy without any severe adverse event.
Survival. There were 176 deaths: 83 in patients assigned to pyrimethamine and 93 in those assigned to placebo. The l-year survival rate was 85% (95% CI, 80%-89%) in the pyrimethamine group and 80% (95% CI, 75%-85%) in the placebo group (RR, 0.9; 95% CI, 0.7-1.2; P = 042; table 2). The apparent causes of death, in particular those deaths related to toxoplasmosis, were not different between groups.
After adjustment for baseline characteristics, survival was not influenced by treatment group or originating country, while other factors appeared independently predictive of death: increased age (for a lO-year difference: RR, 1.3; 95% CI, 1.1-104), AIDS compared with asymptomatic HIV infection (RR, 2.3; 95% CI, 1.7-6.2), CD4 cell count (for every 50-cells/mm 3 decrease: RR, 104; 95% CI, 1.3-1.5), hemoglobin level (for every 1 g/dL decrease: RR, 1.2; 95% CI, 1.1-104), and no zidovudine therapy versus zidovudine therapy at baseline (RR, 1.6; 95% CI: 1.1-2.3).
Adverse events. Seventy-five patients had an adverse event requiring discontinuation of the study drug: 55 in the pyrimethamine group and 20 in the placebo group (table 2). The estimated l-year incidence of treatment-limiting adverse events was 20% in the pyrimethamine group and 7% in the placebo group. The l-year incidence of rash was significantly different between the 2 groups: 7% (n = 20) in the pyrimethamine group and 1% (n = 3) in the placebo group. Seventeen of the 20 rashes occurred within 2 months after initiation of pyrimethamine (median time to onset: 42 days; range, 4-319). Of the 20 rashes in the pyrimethamine group, 7 had a severity grade of 3. No grade 3 rashes were reported in the placebo group. There was a trend toward a higher rate of occurrence ofhematologic and gastrointestinal adverse events in the pyrimethamine group, although the difference between the 2 groups was not significant. The mean cumulative daily dose of zidovudine during the first 12 months was not different in the 2 groups: 547 ± 200 and 567 ± 200 mg/day in the pyrimethamine and placebo groups, respectively ( P = A).
Predictive factors for TE in the placebo group. After multivariate analysis, absolute CD4 cell count and symptomatic HIV infection (CDC stage IV) appeared to be independent risk fac- tors for TE: CD4 cell count of <50 cells/mnr' compared with >50 cells/mm' (RR, 3.0; 95% CI, 1.6-5.7; P < .001), stage IV non-AIDS compared with asymptomatic HIV infection (RR, 3.1; 95% CI, 1.3-7.4; P = .01), and AIDS compared with asymptomatic HIV infection (RR, 3.2; 95% CI, 1.3-8.1; P = .0I; table 3). However, the percentage of CD4 cells was not in itself an independent predictive factor for TE. The risk became significantly greater for patients with < 100 CD4 cells/mnr' at baseline. Patients who had 100-200 CD4 cells/mnr' were at lower risk of developing TE unless they had clinical manifestations of HIV infection (CDC stage IV) at baseline.
Discussion
In this double-blind, placebo-controlled trial, 50 mg of pyrimethamine administered three times a week in conjunction with folinic acid did not significantly influence survival or the risk of acquiring TE. We therefore conclude that pyrimethamine at this dose should not currently be recommended as a first-line regimen for primary prophylaxis of toxoplasmosis.
An intriguing finding in the present trial is the discrepancy between the intention-to-treat analysis, which showed no effect, and the on-treatment analysis, which demonstrated a lower rate of TE for patients randomized to pyrimethamine during the period they were taking active drug. Several interpretations are possible, but caution must be used because only the standard intention-to-treat approach allows unbiased comparisons of all patients in each group [21] . Compliance, as assessed by punctual measurements of pyrimethamine serum levels, was good and cannot explain this discrepancy. Patients who discontinued pyrimethamine because of an adverse event, particularly rash, were significantly more likely to develop TE than those receiving placebo, whereas the prevalence of TE was low in patients who tolerated and continued pyrimethamine. These disparate findings may indirectly provide evidence of the effectiveness of pyrimethamine. On the other hand, patients who continue pyrimethamine may represent a selected subgroup of patients at lower risk for TE, while the patients with rash represent a selected subgroup with a higher risk of TE than patients in the placebo arm [22] .
The serum half-life of pyrimethamine varies from 24 to 200 h among HIV-infected patients [16, 23] . Persons with short pyrimethamine half-lives may require a higher dose or a shorter interval between doses (or both) to achieve drug levels required to prevent reactivation of Toxoplasma infection. Whether higher dosages of pyrimethamine (e.g., 50 mg/day) might be more effective with an acceptable tolerance remains questionable [24] .
The dosage of pyrimethamine used in the trial was selected because of its potential in vivo effect against T gondii and favorable toxicity profile [12, 21, 23] . This dosage appeared to be well tolerated. Rash was the only significant adverse event associated with pyrimethamine, although its annual incidence (7%; 95% CI, 5%-11 %) was moderate, similar to other trials of pyrimethamine [25, 26] .
There was a trend toward a greater frequency of hematologic toxicity in the pyrimethamine group than in the placebo group, but the difference was not statistically significant. Since folate deficiency is commonly associated with pyrimethamine use, the similar rate of hematologic toxicity among the 2 groups was probably the result of concomitant folinic acid administration. Folinic acid is usually given to patients receiving pyrimethamine, although its use is based on little clinical data and it is expensive.
The rate of mortality was similar among the groups in this study. Jacobson et a1. [25] recently reported a higher rate of mortality in patients randomized to receive pyrimethamine at a lower dose and without routine folinic acid than in patients randomized to placebo. The use of pyrimethamine without folinic acid and the concomitant use of other drugs, such as cotrimoxazole or dapsone, may have contributed to the increased risk of death in that study. Of note, the baseline level of hemoglobin was a significant predictor of survival in our study and the one by Jacobson et a1. [25] . By preventing anemia, folinic acid may have decreased the risk of mortality in our study. These data provide further evidence to support the use of at least 15 mg offolinic acid per 50 mg of pyrimethamine three times a week to counteract the antifolate activity of longterm pyrimethamine therapy [13, 27] .
Another important factor that adversely affected survival was increased age, a well established factor for poor prognosis in patients with HIV infection. The favorable influence of baseline antiretroviral therapy on survival was confirmed in this study, reinforcing the recommendation to initiate antiretroviral nn 1996; 173 (January) therapy when a patient's CD4 cell count decreases to <200 cells/mrrr' [28, 29) .
This study provides the first prospective data identifying risk factors for the occurrence of TE. The l-year incidence of TE in this study (13%) was higher than expected [6] . As with Pneumocystiscariniipneumonia [30] , the risk oftoxoplasmosis increased as the CD4 cell count decreased. Risk was also correlated with symptomatic HIV infection (CDC stage IV) at baseline. Thus, determining the serologic status for T. gondii of HIV-infected patients at least once is useful to select candidates who could benefit from toxoplasmosis prophylaxis. In patients who are seropositive for T. gondii, primary prophylaxis against toxoplasmosis is appropriate when their CD4 lymphocyte count decreases to < 100 cells/mm', regardless of clinical status. Toxoplasma-seropositive patients with clinical manifestations of HIV infection, particularly AIDS-defining opportunistic infections and malignancies, should receive prophylaxis when their CD4 cell count is <200 cells/mnr'.
The selection of an appropriate prophylactic regimen, however, remains problematic. Data accumulated over the last 3 years suggest that cotrimoxazole may be an effective agent for primary prophylaxis against T. gondii. Although the efficacy of cotrimoxazole in preventing TE has not been demonstrated in an intention-to-treat analysis of a randomized study, the rate of toxoplasmosis has been low [15, 31, 32] among patients who tolerated long-term treatment with the drug. Its efficacy has been clearly demonstrated for primary and secondary prophylaxis of pneumocystosis [IS, 19, 31, 33, 34) .
Since 10%-30% of patients cannot tolerate cotrimoxazole, alternative regimens are urgently needed for primary prophylaxis against TE. A combination ofpyrimethamine and dapsone has proven effective for preventing pneumocystosis and toxoplasmosis [26) . However, adverse effects are also associated with dapsone [35] , and it is not tolerated in up to 40% of patients experiencing treatment-terminating adverse reactions to cotrimoxazole [36] .
The risk of TE increases significantly and the need for effective prophylaxis is greatest in patients with < 100 CD4 cells/ mm'. Since there was a trend (although not significant) toward a beneficial effect ofpyrimethamine in this subgroup, pyrimethamine should be considered for similar patients with demonstrated intolerance to cotrimoxazole. Further study will be required to define the exact role of pyrimethamine in preventing toxoplasmosis.
